XTRENBO Trademark

Trademark Overview

On Tuesday, July 18, 2023, a trademark application was filed for XTRENBO with the United States Patent and Trademark Office. The USPTO has given the XTRENBO trademark a serial number of 98091091. The federal status of this trademark filing is REGISTERED as of Tuesday, June 16, 2026. This trademark is owned by Hikma Pharmaceuticals USA Inc.. The XTRENBO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of bone disease, oncological and metabolic diseases and disorders, and complications associated therewith
xtrenbo

General Information

Serial Number98091091
Word MarkXTRENBO
Filing DateTuesday, July 18, 2023
Status700 - REGISTERED
Status DateTuesday, June 16, 2026
Registration Number8305679
Registration DateTuesday, June 16, 2026
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 30, 2024

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of bone disease, oncological and metabolic diseases and disorders, and complications associated therewith

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 17, 2023
Primary Code005
First Use Anywhere DateSunday, August 31, 2025
First Use In Commerce DateMonday, January 19, 2026

Trademark Owner History

Party NameHikma Pharmaceuticals USA Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressBerkeley Heights, NJ 07922
US
Party NameHikma Pharmaceuticals USA Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBerkeley Heights, NJ 07922
US
Party NameHikma Pharmaceuticals USA Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBerkeley Heights, NJ 07922
US

Trademark Events

Event DateEvent Description
Friday, July 21, 2023NEW APPLICATION ENTERED
Thursday, August 17, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, March 22, 2024ASSIGNED TO EXAMINER
Monday, March 25, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 10, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 30, 2024PUBLISHED FOR OPPOSITION
Tuesday, April 30, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 25, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, November 21, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, November 21, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, November 21, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, December 9, 2024SOU TEAS EXTENSION RECEIVED
Monday, December 9, 2024SOU EXTENSION 1 FILED
Monday, December 9, 2024SOU EXTENSION 1 GRANTED
Monday, December 9, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 23, 2025SOU TEAS EXTENSION RECEIVED
Monday, June 23, 2025SOU EXTENSION 2 FILED
Monday, June 23, 2025SOU EXTENSION 2 GRANTED
Monday, June 23, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 3, 2025SOU TEAS EXTENSION RECEIVED
Wednesday, December 3, 2025SOU EXTENSION 3 FILED
Wednesday, December 3, 2025SOU EXTENSION 3 GRANTED
Thursday, December 4, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 22, 2026TEAS STATEMENT OF USE RECEIVED
Monday, May 25, 2026CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, January 22, 2026USE AMENDMENT FILED
Monday, May 25, 2026STATEMENT OF USE PROCESSING COMPLETE
Wednesday, May 27, 2026ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, May 27, 2026NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, June 16, 2026REGISTERED-PRINCIPAL REGISTER
Tuesday, June 16, 2026NOTICE OF REGISTRATION CONFIRMATION EMAILED

Related Keywords

xtrenbo disorders diseases complications associated therewith metabolic oncological preparations treatment bone